Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MAMH - New Breast Cancer detection method -- Ignore unavailable to you. Want to Upgrade?

To: Susan Bruce who wrote (530)	7/13/1998 2:21:00 PM
From: Cool Penny	Respond to of 971

I would like more news also, but here is a little from their 10k until we hear more During the quarter,the Company extended its relationship with its German distributor by training 3 health care professionals (two physicians and one nurse) as MammaCare Specialists. This will provide the basis for extensive outreach to the medical community in Germany which will, the Company hopes, help solidify acceptance of the MammaCare technology among the women of that country.The Company also trained six additional specialists, including a physician from a major medical school who will be introducing the MammaCare method of clinical breast examination to resident training in that institution. The Company also made a substantial sale of breast models and other training materials to the American Medical Women's Association for their use in training U.S. military personnel and their dependents. Many of these are follow-up orders from similar sales made last year. The Company made a major sale of specially constructed breast models to the California Department of Health. That organization is actively disseminating a program of clinical breast examination training using the Company's products and procedures.There can be no assurance, however, that any of these customers will continue to procure materials at the present rate or that substantial revenues will accrue to the Company as a result of their involvement. Finally, the Company introduced two new products during the quarter. It has added dark-skinned models to the Home Practice Series in response to numerous requests, particularly from American Cancer Society units. It also added a new evaluation lamp which projects the MammaCare grid on the torso of the patient being trained or examined. This grid provides a basis for precise measurement of the examination performance, a hallmark of the MammaCare procedure since its days in the laboratory. The Company remains essentially debt-free and has no immediate liquidity problems. It continues to pursue a corporate affiliation designed to help it realize the full commercial potential of its products. I'm sure more new will follow but don't know what it will be!